Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).

  PMID 38897205 · PMC11293361 · Cell reports. Medicine · 2024 · 8 claims · 8 setups

  Has reproduction · 72

  Neoadjuvant sintilimab plus carboplatin/nab-paclitaxel is clinically feasible and tolerable in resectable EGFR-mutant NSCLC, with all 18 patients completing treatment and undergoing radical surgery.

  pre resected tumor serial whole-exome bulk single-cell

• Reinvigorating COTL1(high) NK cells via GITR signalling overcomes immune checkpoint blockade resistance in tsMHC-I-impaired tumours.

  PMID 41912896 · PMC13179135 · Nature cell biology · 2026 · 8 claims · 8 setups

  Full-text index only

  A COTL1-high NK cell subset mediates immune checkpoint blockade responsiveness in tsMHC-I impaired tumours

  hcc sorted orthotopic multiplex bulk single-cell

• PD-1 blockade plus tyrosine kinase inhibitor remodels the tumor microenvironment in advanced renal cell carcinoma.

  PMID 41916996 · PMC13199584 · Nature communications · 2026 · 8 claims · 8 setups

  Full-text index only

  Non-responders to TKI±ICI therapy show increased neutrophil infiltration and enrichment of SAA+ tumor cells after treatment.

  arcc pre post-treatment tumor single-cell multiplex ligand-receptor

• PRDM1+ Malignant Cells Mediate an Immunosuppressive Landscape and Resistance to Neoadjuvant Chemoradiotherapy and Immunotherapy in Esophageal Squamous Cell Carcinoma.

  PMID 41556358 · PMC13042517 · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026 · 8 claims · 8 setups

  Full-text index only

  A PRDM1+ malignant epithelial cell subcluster (Epi_C4) is enriched in NMPR patients and is associated with nICRT treatment resistance

  locally escc pd-1 kyse-30 single-arm scrna-seq bulk

• Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers.

  PMID 41484081 · PMC12858953 · Nature communications · 2026 · 8 claims · 8 setups

  Full-text index only

  Combined low-dose CTX + anti-CSF-1R (SNDX-ms6352) is highly effective against aggressive metastatic Trp53-null TNBC models with high macrophage infiltration, producing complete tumor regression in claudin-low models.

  trp53-null complete t12 cell-deficient imaging survival tumor

• Sequential transcriptional waves and NF-κB-driven chromatin remodeling direct drug-induced dedifferentiation in cancer.

  PMID 41986344 · PMC13083995 · Nature communications · 2026 · 8 claims · 8 setups

  Full-text index only

  BRAFi (vemurafenib) treatment drives BRAF-mutant melanoma cells through a reversible dedifferentiation transition from a melanocytic state through a neural crest-like state to a drug-tolerant mesenchymal state

  m397 patient-derived longitudinal time-series atac-seq chip-seq